Department of Endocrinology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Department of Otorhinolaryngology, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Osteoporos Int. 2019 Jul;30(7):1511-1519. doi: 10.1007/s00198-019-04959-y. Epub 2019 Apr 10.
Diagnosis of parathyroid carcinoma on histological examination is challenging. Thousands of differentially expressed lncRNAs were identified on the microarray data between parathyroid cancer and adenoma samples. Four lncRNAs were significantly dysregulated in further validation. The "lncRNA score" calculated from these lncRNAs differentiated parathyroid carcinomas from adenomas. LncRNAs serve as biomarkers for parathyroid cancer diagnosis.
Diagnosis of parathyroid carcinoma (PC) on histological examination is challenging. LncRNA profile study was conducted to find diagnostic biomarkers for PC.
LncRNA arrays containing 91,007 lncRNAs as well as 29,857 mRNAs were used to assess parathyroid specimen (5 carcinomas and 6 adenomas). Bioinformatics analyses were also conducted to compare the microarray results between parathyroid carcinomas and adenomas (PAs). Differentially expressed lncRNAs of 11 PCs and 31 PAs were validated by real-time quantitative PCR.
On the microarray data between PC and PA samples (fold change ≥ 2, P < 0.05), 1809 differentially expressed lncRNAs and 1349 mRNAs also were identified. All carcinomas were clustered in the same group by clustering analysis using dysregulated lncRNAs or mRNAs. Four lncRNAs (LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1) identified were significantly dysregulated in further RT-PCR validation. The global "lncRNA score" calculated from the lncRNAs above also differentiated parathyroid carcinomas from adenomas.
LncRNA profiling shows distinct differentially expressed lncRNAs in parathyroid neoplasm. They may play a key role in parathyroid cancer and serve as potential biomarkers to distinguish parathyroid cancers from parathyroid adenomas.
在组织学检查中诊断甲状旁腺癌具有挑战性。在微阵列数据中，甲状旁腺癌和腺瘤样本之间鉴定出数千个差异表达的长链非编码 RNA。在进一步验证中，有 4 个长链非编码 RNA 显著失调。从这些长链非编码 RNA 计算得出的“长链非编码 RNA 评分”可将甲状旁腺癌与腺瘤区分开来。长链非编码 RNA 可作为甲状旁腺癌诊断的生物标志物。
在组织学检查中诊断甲状旁腺癌 (PC) 具有挑战性。进行长链非编码 RNA 谱研究以寻找 PC 的诊断生物标志物。
使用包含 91007 个长链非编码 RNA 和 29857 个 mRNA 的长链非编码 RNA 阵列来评估甲状旁腺标本 (5 例癌和 6 例腺瘤)。还进行了生物信息学分析，以比较甲状旁腺癌和腺瘤 (PA) 之间的微阵列结果。通过实时定量 PCR 验证了 11 例 PC 和 31 例 PA 的差异表达长链非编码 RNA。
在 PC 和 PA 样本之间的微阵列数据中（倍数变化≥2，P<0.05），还鉴定出 1809 个差异表达的长链非编码 RNA 和 1349 个 mRNA。使用失调的长链非编码 RNA 或 mRNA 进行聚类分析后，所有癌均聚类在同一组中。在进一步的 RT-PCR 验证中，有 4 个长链非编码 RNA（LINC00959、lnc-FLT3-2:2、lnc-FEZF2-9:2 和 lnc-RP11-1035H13.3.1-2:1）显著失调。从上述长链非编码 RNA 计算得出的整体“长链非编码 RNA 评分”也可区分甲状旁腺癌和腺瘤。
长链非编码 RNA 谱显示出甲状旁腺肿瘤中存在明显差异表达的长链非编码 RNA。它们可能在甲状旁腺癌中发挥关键作用，并可作为潜在的生物标志物，将甲状旁腺癌与甲状旁腺瘤区分开来。
